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Abstract
Purpose—Androgen receptor (AR) abundance and AR-regulated gene expression in castration-
recurrent prostate cancer (CaP) are indicative of AR activation in the absence of testicular androgen.
AR transactivation of target genes in castration-recurrent CaP occurs in part through mitogen
signaling that amplifies the actions of AR and its coregulators. Herein we report on the role of
14-3-3η in AR action.
Experimental Design and Results—AR and 14-3-3η co-localized in COS cell nuclei with and
without androgen and 14-3-3η promoted AR nuclear localization in the absence of androgen.
14-3-3η interacted with AR in cell-free binding and coimmunoprecipitation assays. In the recurrent
human CaP cell line, CWR-R1, native endogenous AR transcriptional activation was stimulated by
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Statement of Translational Relevance We demonstrate that 14-3-3η is an androgen receptor (AR) coactivator in post-castration
recurrent prostate cancer (CR-CaP) through its direct interaction with AR and by augmenting mitogen effects on AR transcriptional
activity. The use of AR siRNA technology in the experimental setting as well as in recent phase 1 clinical trials with a CYP17 inhibitor
of androgen production provide strong evidence that AR action is central to the growth of CR-CaP. Our studies identify a new potential
target to inhibit CR-CaP growth. We demonstrate that 14-3-3η causes AR to be nuclear in the absence of androgen, whereas without
14-3-3η, AR is cytoplasmic. We demonstrate also that AR signaling increases the production of 14-3-3η through the synthesis of new
mRNA and that 14-3-3η levels remain elevated together with AR in CR-CaP. Studies described in this report provide a potential new
target for combination therapy to block the AR driven growth of CR-CaP.
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14-3-3η at low DHT concentrations and was increased by EGF. Moreover, the DHT and EGF
dependent increase in AR transactivation was inhibited by a dominant negative 14-3-3η. In the
CWR22 CaP xenograft model, 14-3-3η expression was increased by androgen, suggesting a feed-
forward mechanism that potentiates both 14-3-3η and AR actions. 14-3-3η mRNA and protein
decreased following castration of tumor bearing mice and increased in tumors of castrate mice after
treatment with testosterone. CWR22 tumors that recurred 5 months after castration contained
14-3-3η levels similar to the androgen-stimulated tumors removed before castration. In a human
prostate tissue microarray of clinical specimens, 14-3-3η localized with AR in nuclei and the similar
amounts expressed in castration-recurrent CaP, androgen-stimulated CaP and benign prostatic
hyperplasia were consistent with AR activation in recurrent CaP.
Conclusion—14-3-3η enhances androgen and mitogen induced AR transcriptional activity in
castration-recurrent CaP.
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Introduction
The androgenic steroid hormones, testosterone and its more active metabolite
dihydrotestosterone (DHT), maintain and stimulate growth of prostate cancer cells. Removal
of the testicular source of circulating androgens by medical or surgical castration causes
regression of androgen-dependent prostate cancer (1). However, androgen deprivation therapy
is only palliative since prostate cancer recurs (referred to as castration-recurrent prostate
cancer) and almost always causes death. The expression of AR (2–6) and androgen-regulated
genes (7,8) in castration-recurrent cancer implicates AR signaling in recurrent growth despite
low levels of circulating androgen. Potential mechanisms include AR gene amplification (9),
gain of function mutations in the AR gene resulting in promiscuous ligand binding (6,10, see
also www.androgendb.mcgill.ca), coactivator overexpression (11), intracrine production of
testosterone and DHT (12,13) and enhanced activation of AR through mitogen signaling
(14–17).
The 14-3-3 family of homo or heterodimeric α-helical proteins interact with a variety of
signaling proteins including kinases, phosphatases, transcription factors and non-kinase
receptors (18). 14-3-3 proteins were the first to be identified as phosphoserine/threonine motif
binding proteins. Three recognition motifs for 14-3-3 have been identified, however 14-3-3
target proteins do not always contain sequences that conform to these motifs or require
phosphorylation for interaction with 14-3-3 (18,19). Possible modes of action of 14-3-3 on
target proteins include directed conformational change, modification of nuclear/cytoplasmic
localization, physical occlusion of sequence-specific interactive regions and scaffolding (20,
21). 14-3-3 binding often leads to client protein stabilization or altered subcellular localization
that in many cases alters protein function. Some 14-3-3 isoforms have been directly associated
with tumorigenesis and may serve as targets for cancer therapy (22).
CWR22 is an androgen-dependent human prostate cancer xenograft model propagated in male
nude mice (23). After castration of the tumor bearing male host, prostate-specific antigen
protein and mRNA decrease rapidly and CWR22 xenograft tumors regress in size (24,7) but
within 5 months undergo recurrent growth in the absence of testicular androgens, a progression
pattern that resembles the recurrence of prostate cancer in humans but in a shorter timeframe
(23). Castration-recurrent CWR22 tumors remain androgen responsive and an androgen
sensitive cell line, CWR-R1 (25) was developed from a recurrent CWR22 xenograft tumor.
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Herein we demonstrate that 14-3-3η (eta) is a human AR binding protein in CWR-R1 cells
(25) and that 14-3-3η binding to AR is associated with increased AR transcriptional activity
that is enhanced by epidermal growth factor (EGF) and DHT. We found that the expression of
14-3-3η was androgen dependent in the androgen-dependent CWR22 xenograft tumor and
decreased after castration but reappeared in the castration-recurrent CWR22 tumor despite the
absence of circulating testicular androgen. In addition, clinical samples of castration-recurrent
cancer revealed amounts of 14-3-3η similar to the amounts expressed in androgen-stimulated
benign prostate and androgen-stimulated prostate cancer. The results indicate that AR regulates
the expression of 14-3-3η and that AR regulation is active in castration-recurrent prostate
cancer. 14-3-3η localizes with AR in nuclei and provides a link between EGF signaling and
AR transcriptional activation in prostate cancer.
Material and Methods
Plasmid construction
Full-length 14-3-3η (18) was excised from the vector pPCR-Script Amp 14-3-3η using EcoR1
and Sac1. The excised DNA was blunt ended with Klenow enzyme (Life Technologies, Inc.
Rockville, MD), and ligated into the blunt ended BamH1 site of pSG5 (Stratagene, La Jolla,
CA). Sense and antisense constructs were verified by automatic sequencing using a Perkin-
Elmer Corp. Model 377 DNA sequencer. A dominant negative double arginine mutant of
human 14-3-3η cDNA (pcDNA3.1-myc-14-3-3η-R56, 60A) was obtained from Andrey S.
Shaw, Washington University, St. Louis, MO.
Solid-phase binding assays
Purified full-length human hexahistidine-tagged 14-3-3η or 14-3-3ζ (zeta) was incubated with
Ni+2-charged Sepharose 6B beads (Novagen, San Diego, CA) for 1 hour at 4°C. Radiolabeled
AR was generated using the TNT in vitro transcription-translation system (Promega, Madison,
WI). The full-length DNA template pSG5-AR was incubated with TNT rabbit reticulocyte
lysates in the presence of 35S-methionine. For the binding assays (26), the immobilized
14-3-3η or 14-3-3ζ protein (1 μg each) was mixed with 35S-labeled AR in Nonidet P-40 buffer
(1% Nonidet P-40, 137 mM NaCl, 1 mM MgCl2, and 40 mM Tris-HCl (pH 8.0) for 1 hour at
4°c with rotation. 14-3-3η or 14-3-3ζ complexes were washed 3 times with Nonidet P-40 buffer
and 3 times with radioimmune precipitation assay wash (1% Nonidet P-40, 137 mM NaCl,
0.5% sodium deoxycholate, 0.1% SDS, and 20 mM Tris-HCL (pH 8.0)), and boiled 5 min in
2x SDS sample buffer before resolution by SDS-PAGE (12%). Gels were dried and
autoradiography performed with BioMax film (Eastman Kodak Co. Rochester, NY) at −80°
C. Image analysis was performed using the Personal Densitometer SI (Molecular Dynamics,
Sunnyvale, CA).
Immunoprecipitation and immunoblot analysis
Protein lysates were prepared from COS cells grown on 10 cm culture dishes and cotransfected
with sense or antisense 14-3-3η and human AR expression vectors as described (27). COS cells
were derived from CV1 cells by transformation with replication origin defective SV40 virus
that codes for large T antigen. Thus, expression vectors containing the SV40 origin of
replication, when transiently transfected into COS cells are replicated to multiple copies/cell.
COS cell lysates were precleared with mouse IgG and protein A-agarose. To examine AR/
14-3-3η complex formation in COS cell and CWRR1 cell lysates, anti-14-3-3 antibody that
recognizes η and γ isoforms (Santa Cruz Biotechnology Inc., Santa Cruz, CA, sc-731) or anti-
actin antibody (Research Diagnostic Inc., Flanders, NJ) were incubated with rotation for 1 hour
followed by the addition of protein A-agarose with constant rotation at 4°C overnight.
Immunoblot analysis was performed using AR monoclonal antibody (Biogenex, San Ramon,
CA) at 1:5000 dilution and secondary antibody (horseradish-peroxidase conjugated anti-
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mouse, Promega Corporation, Madison, Wis.) at 1:10000 dilution. Antigen-antibody
complexes were detected using enhanced chemiluminescence (DuPont, NEN Research
Products, Boston, MA).
Prostate cancer specimens were pulverized in liquid nitrogen and mixed with 0.5 mL of
radioimmunoprecipitation assay buffer containing Complete™ protease inhibitors (Roche,
Indianapolis, IN) (11). Tissue was homogenized for 30 sec on ice, incubated for 45 min on ice
and centrifuged at 10000 × g for 20 min twice at 4°C to remove nuclei and insoluble material.
Proteins were separated by electrophoresis on 10% acrylamide gels, electroblotted and
immunoblot analysis performed as described above using 14-3-3η antibody specific for the
η isoform (Santa Cruz sc-17287).
Transient cotransfection assays
Cotransfection assays using monkey kidney epithelial CV1 cells were performed as described
(10) with minor modifications. We have used the CV1 cell line as a reference standard for
cotransfection assays with different cell lines. In brief, CV1 cells were maintained at 37°C
under 5% CO2 in DMEM-H medium containing 2 mM L-glutamine, 10% bovine calf serum,
20 mM HEPES, 100 units/mL of penicillin and 100 μg/mL streptomycin. On the day before
transfection, 4.5 × 106 cells per 6 cm culture dish were grown in the same medium for about
20 hours until 70% confluent. 0.25 μg probasin-luciferase vector, 0.25 μg human AR
expression vector (pSG5-hAR), and 0.5 μg of pSG5-14-3-3η sense or pSG5-14-3-3η antisense
vector per 6 cm culture dish were cotransfected using the Effectene (Qiagen, Valencia, CA)
method. After incubation for 24 hours the medium was changed to DMEM-H without phenol
red plus 5% charcoal stripped serum in the presence or absence of steroid and the cells were
incubated for 40 hours.
CWR-R1 cells were maintained in prostate growth medium [DMEM-H (Gibco/Invitrogen)
containing linoleic acid 0.1 μg/mL, L-glutamine 2 mM, nicotinamide 1.2 μg/mL, insulin 5
μg/mL, transferrin 5 μg/mL, selenium 5 ng/mL, 100 units/mL penicillin, 100 μg/mL
streptomycin, 20 mM HEPES, pH 7.2, FBS 2% and EGF (mouse, BD Biosciences) 10 ng/mL].
Transient transfections were performed as described (27) with minor modifications. CWR-R1
cells were plated the day before at 106 cells per 6 cm culture dish in prostate growth medium
without EGF and grown for about 20 hours to approximately 70% confluence (27). Cells were
cotransfected with the prostate specific antigen PSA-luciferase (referred to previously as PSE-
Luc) reporter (0.5 μg) and 250 ng pSG5-14-3-3η sense or 14-3-3η antisense using the Effectene
method. CWR-R1 cells were cotransfected similarly with MMTV-luciferase reporter (0.5 μg)
and 250 ng pSG5-14-3-3η sense or antisense. CWR-R1 transfection medium was replaced with
phenol red-free, serum-free medium (27, Improved MEM Zinc Option; Invitrogen, Carlsbad,
CA) with or without addition of DHT or EGF as indicated and incubated 24 hours.
Cells were harvested in lysis buffer (Promega), and luciferase activity was measured using a
luminometer. Luciferase activity in representative assays was expressed as mean and standard
deviation of optical units from 3 replicates in the presence of hormone compared with replicates
in the absence of hormone.
Prostate tissue specimens
All prostate specimens were acquired in compliance with the guidelines of the University of
North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Clinical Protocol
Review Committee, Institutional Review Board, Federal Health Insurance Portability
Accountability Act (HIPAA) and Protected Health Information (PHI) Regulations. CWR22
human prostate cancer xenografts were propagated and procured as described (7,23,27) in
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compliance with approved protocols and regulations of the University of North Carolina School
of Medicine at Chapel Hill IACUC committee.
Immunostaining of tissue sections
Formalin-fixed, paraffin-embedded xenograft tumors were sectioned and stained using
standard immunohistochemical techniques. Method for Fig. 4 panel B, 1–4: After being
deparaffinized and rehydrated, tissue sections (8 μm) were incubated in epitope-retrieval buffer
(AntigenDecloaker, pH 6.0; Biocare Medical, Walnut Creek, CA) in a decloaking chamber
(Biocare Medical) at 120°C for 5 min. Sections were pretreated with 3% hydrogen peroxide,
5% normal horse serum and avidin-biotin blocking reagents (Vector Laboratories, Burlingame,
CA). Rabbit polyclonal anti-14-3-3η antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
sc-731 was used at 2 μg/mL (1:100). After incubation with biotinylated goat anti-rabbit IgG,
immunostaining was amplified using Vector Laboratories Elite ABC kit and the
immunoperoxidase complex was visualized using diaminobenzidine. Counterstaining was
performed with hematoxylin. Method for Fig. 4 panel C, 1–6: tissue sections (8 μm) were
incubated in 83% methanol and 5% H2O2 at room temperature for 30 min to reduce endogenous
peroxidase activity, followed by exposure to 0.01 M sodium citrate, pH 6.0 for 15 min in a
microwave oven at high setting. For 14-3-3η detection using goat polyclonal anti-14-3-3η
antibody (Santa Cruz Biotechnology, Santa Cruz, CA sc-17287, lot #K1803), sections were
blocked with 1.5% normal rabbit serum and incubated overnight at 4°C in a humidified
chamber with 14-3-3η antibody at 0.4 μg/mL (1:500), washed with PBS and blocked again
with 1.5% normal rabbit serum. After incubation for 30 min with biotinylated rabbit antigoat
IgG, immunostaining was amplified using the Vector Laboratories Elite ABC Kit and the
immunoperoxidase complex was visualized using diaminobenzidine (DAB). Sections were
exposed to osmium vapors and counterstained with 0.05% toluidine blue in 30% ethanol,
dehydrated, cleared in xylene and mounted with Permount (Fisher). For AR immunostaining
using rabbit polyclonal anti-AR-PG21 (Upstate USA, Inc., Lake Placid, NY cat. #06-680),
sections were blocked with 2% normal goat serum and incubated overnight at 4°C in a
humidified chamber with AR-PG21 antibody at 0.75 μg/mL (1:200). Sections were washed
with PBS and blocked again with 2% normal goat serum. Following incubation with
biotinylated goat anti-rabbit IgG, immunostained AR-PG21 was amplified using Vector
Laboratories Standard ABC kit. Sections were treated as above from the DAB step to the end
of the staining protocol. Photographs (40X) were taken using a SPOT-4 Megapixel Digital
Color Camera System (Diagnostic Instruments, Inc., Sterling Heights, MI) attached to a Nikon
ECLIPSE E600 microscope and prepared using SPOT image processing software.
Tissue microarray construction, immunostaining and image acquisition were performed as
described (5,28,29) using 14-3-3η specific antibody sc-17287, lot #K1803. Tissue microarray
sections were visually scored by three individuals without knowledge of tumor or patient status.
Epithelial cell 14-3-3η nuclear and cytoplasmic immunostaining was assessed using a scale
ranging from 0 (no expression) to 3 (strong expression) in each of 100 cells yielding a visual
score ranging from 0 to 300.
Immunofluoresence microscopy
Assays were performed using COS cells as described (30). Cells were grown in DMEM-H
(Gibco/Invitrogen) containing 2 mM L-glutamine, 20 mM HEPES buffer pH 7.2, 100 units/
mL penicillin, 100 μg/mL streptomycin and 5% bovine calf serum and 10,000 cells/well were
seeded on coverslips (Microscope coverglass, Fischer Scientific, Pittsburg, PA) in 12-well
plates and cultured in the same medium. The following day, DEAE-dextran followed by
glycerol shock was used to transfect 1 μg each of pCMV-AR, pSG FLAG-14-3-3η, pSG FLAG-
CRIF1 or pSG FLAG alone and in the combinations shown in Fig. 1D. Cells were washed two
times with TBS and incubated in DMEM-H with or without 10 nM DHT and in the absence
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of serum or phenol red. Media were changed the following day and incubations continued for
24 hours. Incubations with primary antibodies (anti-AR 1:250, and/or anti-FLAG 1:1000) were
for 1 hour at room temperature. After washing 3 times with PBS, cells were incubated with
secondary fluorescent antibodies at 1:50 dilution for 30 min at room temperature and images
obtained using a Zeiss LSM 210 confocal microscope. Rabbit anti-AR ab3510 was obtained
from Abcam, Cambridge, MA; mouse anti-FLAG antibodies from Sigma. Fluorescein (FITC)-
conjugated, AffiniPure Donkey Anti-rabbit IgG and Rhodamine (TRITC)-conjugated
AffiniPure Donkey Anti-mouse IgG were from Jackson Immuno Research, West Grove, PA.
Comparative (Ct method) quantitative real-time PCR analysis
Genomic DNA-free total RNA was isolated from archived CWR22 tumors (n=2) from mice
that were intact, 6-days and 12-days after castration, and recurrent tumors from mice 150-days
after castration. TRIzol reagent (Gibco, Rockville, MD) was used according to the
manufacturer's protocol. Total RNA integrity was determined using the Agilent 2100
Bioanalyzer (Agilent, Palo Alto, CA). 14-3-3η mRNA levels were assayed using beta-
glucuronidase (GUS) as calibrator in comparative real-time PCR. PCR was performed in a one
step reaction using 50 ng total RNA and 1 unit of reverse transcriptase (Roche, Indianapolis,
IN) in a total volume of 30 μL [48°C, 30 min; 95°C, 10 min; 40 cycles at 95°C, 15 sec; 63°C,
1 min] using the Applied Biosystems RT-PCR 7500 System (Foster City, CA)]. Specific
primers for amplifying 14-3-3η and GUS were based on human GenBank sequences. Forward
and reverse primer sequences were 14-3-3η, 5'-ttggtgccaggcgatctt and 5'-ccaatttcttttcgtttccatca;
GUS, 5'-tggtgctgaggattggca and 5'-tagcgtgtcgaccccattc.
Statistical analyses
Mean nuclear and cytoplasmic 14-3-3η immunostaining visual scores from human and CWR22
tissue microarrays, mean 14-3-3η mRNA levels in CWR22 tumors and mean densitometry
values for solid phase binding assays were calculated and statistical analysis performed using
Statgraphics Plus 4.1 (Manugistics, Inc., Rockville, MD). The Mann-Whitney comparison test
and students t-test were used and differences were considered significant at P < 0.05.
Results
14-3-3η interacts with AR
His-tag pull down experiments were performed to test for a direct interaction between AR and
14-3-3η protein. Binding of in vitro translated 35S-labeled AR to His-tag 14-3-3η was positive
in the presence of 1 μM DHT compared to the Ni-Sepharose control (P value = 0.013). There
was no difference between control and the minus DHT (Fig. 1A). These results are in agreement
with an earlier report, Zilliacus et al. (31) who showed that AR bound GST-14-3-3η in the
presence of 1 μM testosterone. In addition, we found that under these conditions AR did not
bind the full-length 14-3-3ζ isoform, either in the presence or absence of DHT suggesting a
certain isoform selectivity for AR regulation. Whether AR favors the 14-3-3η isoform within
the 14-3-3 family of proteins remains to be established.
Coimmunoprecipitation studies were performed to test the interaction between AR and
14-3-3η. COS cells were cotransfected with vectors that express recombinant human full-
length wild type AR and either sense or antisense 14-3-3η expression vector DNA. Lysate
proteins were immunoprecipitated with anti-14-3-3 antibody (Santa Cruz sc-731 that
recognizes η and γ isoforms) and immunoblotted with AR antibody. AR co-
immunoprecipitated with 14-3-3η in lysates from COS cells cotransfected with sense
14-3-3η but not with antisense 14-3-3η (Fig. 1B). The amount of AR complexed with
14-3-3η was greater in the presence of DHT while the expression levels (input) of AR and
14-3-3η were similar (Fig. 1C). The AR/14-3-3η association appeared specific in that
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immunoprecipitates with anti-actin instead of anti-14-3-3η antibody did not contain AR. While
the interaction between recombinant wild-type AR and 14-3-3η was stronger in the presence
of DHT (Fig. 1B), complex formation in the absence of DHT suggested the interaction was
not completely androgen dependent.
When recombinant 14-3-3η and AR were expressed separately in COS cells, AR was mainly
cytoplasmic without DHT and nuclear with DHT while 14-3-3η was both nuclear and
cytoplasmic without or with DHT (Fig.1C, upper panel). Co-expression of 14-3-3η and AR in
the absence of DHT resulted in major nuclear localization of AR and co-localization with
14-3-3η in nuclei (Fig. 1C, lower panel). In contrast, an AR corepressor, CR6 interacting
factor-1 (CRIF) localized in nuclei both in the presence and absence of DHT (Fig. 1C, upper
panel) and when co-expressed with AR in the absence of DHT (Fig. 1C, lower panel) CRIF
did not alter the subcellular partitioning of AR. In the presence of DHT, the strong nuclear
localization of AR was not altered by co-expression of 14-3-3η or CRIF.
14-3-3η enhances androgen dependent AR transactivation
To examine the effect of 14-3-3η on the transcriptional function of AR, transient cotransfection
assays were performed in CV-1 cells. In cells transfected with AR together with a probasin-
luciferase reporter gene and the sense 14-3-3η vector, 1 nM DHT increased luciferase activity
3–4 fold greater than in control cells transfected with the antisense 14-3-3η (Fig. 2). In the
absence of DHT, basal luciferase activity in cells transfected with sense 14-3-3η was only
slightly higher than in cells transfected with antisense 14-3-3η. In these experiments, the
antisense 14-3-3η vector DNA was used to balance the sense 14-3-3η vector DNA. The results
indicate that 14-3-3η amplifies DHT induced AR transactivation in CV1 cells.
To investigate the ligand specificity of 14-3-3η stimulation of AR transcriptional activation,
DHT was compared with progesterone, estradiol and the antiandrogen hydroxyflutamide. In
CV1 cell cotransfection assays using the probasin-luciferase reporter gene with DHT,
luciferase activity with sense 14-3-3η was greater than with antisense 14-3-3η. In contrast,
there was little or no increase in luciferase with progesterone, estradiol or hydroxyflutamide.
Similar results were seen at more physiologic ligand concentrations of 0.1 nM (not shown)
suggesting that at the tissue steroid levels found in BPH and prostate cancer (12) it is androgen
induced AR transactivation that is amplified by 14-3-3η.
14-3-3η enhances EGF and DHT induced AR transactivation in a castration-recurrent
prostate cancer cell line
We found in earlier studies that EGF increases DHT dependent AR transcriptional activation
in CWR-R1 cells (27). The EGF effect on AR action involved phosphorylation and increased
coactivation by TIF2/GRIP1. Since 14-3-3 has a propensity for binding to phosphorylated
proteins, we reasoned it might have a role in EGF amplification of AR transactivation. With
this in mind, the effect of 14-3-3η on EGF and DHT induced AR transactivation was determined
in the CWR-R1 cell line. In the presence of the 14-3-3η sense vector, 0.1 nM DHT increased
androgen dependent transcriptional activation of the PSA-luciferase reporter gene about 5-fold
above the no DHT control (Fig. 3A). Concurrent addition of 100 ng/mL EGF and 0.1 nM DHT
further increased AR transcriptional activity 2-fold over that of DHT alone. AR transactivation
in the presence of DHT without or with EGF was greater in the presence of the 14-3-3η sense
vector, than with control 14-3-3η antisense.
Similar 14-3-3η enhancement of AR transcriptional activation was observed using the MMTV-
luciferase reporter gene in CWR-R1 cells (Fig. 3B). MMTV-luciferase was a more sensitive
reporter gene in these cells and enhancement of AR transactivation in the presence of
14-3-3η was observed at lower concentrations of DHT (0.5 pM) and EGF (10 ng/mL).
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14-3-3η with DHT and EGF together increased AR transcriptional activity 6 to 9 fold over
14-3-3η with either DHT or EGF alone. In the same assay, replacing the 14-3-3η sense vector
with the control 14-3-3η antisense resulted in ~50% reduction in AR transactivation.
Endogenous 14-3-3 and AR coimmunoprecipitated in CWR-R1 cell lysates using the
anti-14-3-3η antibody sc-731 and AR-14-3-3 complex formation was increased in the presence
of DHT (Fig. 3C middle panel). However in the presence of DHT, EGF caused no further
increase in coimmunoprecipitation of 14-3-3 with AR (Fig. 3C, lower panel).
Immunoprecipitates with anti-actin antibody instead of anti-14-3-3η antibody did not contain
AR. AR and 14-3-3 protein levels in CWR-R1 cell lysates are shown by immunoblot analysis
(Fig. 3C, upper panel). The results suggest that endogenous 14-3-3η and AR form a complex
in CWR-R1 cells.
Since the native endogenous 14-3-3η appeared to interact with AR in CWR-R1 cells, we used
a dominant negative 14-3-3η to determine the effect of inhibiting endogenous 14-3-3η on AR
transcriptional activation. In transient transfection assays, dominant negative 14-3-3η (DN)
inhibited DHT and DHT+EGF stimulation of MMTV-luciferase transcription (Fig. 3D, left
panel). Moreover, dominant negative 14-3-3η inhibition of the DHT+EGF stimulated
transcriptional activity was prevented by over expression of 14-3-3η (Fig. 3D, right panel).
14-3-3η expression is androgen receptor regulated in the CWR22 human prostate cancer
xenograft specimens
14-3-3η mRNA levels measured by quantitative PCR paralleled the changes in 14-3-3η protein
detected by immunostaining. RT-PCR demonstrated a decrease in 14-3-3η mRNA in CWR22
xenografts within 6 days after castration, P value < 0.001 (Fig. 4 panel A) and an increase
within 48 hours following testosterone treatment of the castrated mice, P value < 0.01. In
CWR22 xenograft tumors that recurred after castration (CR), 14-3-3η mRNA was higher than
in tumors from 6-day or 12-day castrate mice and similar to the levels in androgen-stimulated
tumors from mice prior to castration (Intact).
CWR22 prostate cancer xenograft tumor sections were immunostained with antibody sc-731,
that recognizes 14-3-3η and γ isoforms (Fig. 4 panel B), and with sc-17287, specific for
14-3-3η (Fig. 4 panel C). Tumors from androgen-stimulated intact mice exhibited strong
14-3-3 immunostaining with sc-731 (B-1). Within 6 days after castration of the host, 14-3-3
levels decreased (B-2) and 14-3-3 reappeared within 48 hours after treatment of 6-day castrate
mice with testosterone (B-3) consistent with the increase in RNA and indicating that the
expression of 14-3-3η is androgen regulated. In the castration-recurrent CWR22 xenograft
tumor, the intensity of 14-3-3η immunostaining increased despite the absence of testicular
androgen (B-4) and was similar to the levels in CWR22 xenograft tumors from androgen-
stimulated mice. Higher magnification images of the CWR22 xenograft tumors stained with
14-3-3η specific antibody sc-17287, lot #K1803 (Fig. 4 panel C, 1–3) are shown together with
AR (Fig. 4 panel C, 4–6) in sections from the same tissue blocks. There was strong nuclear
localization of 14-3-3η and AR in the androgen-stimulated (Fig. 4 panel C, 1 and 4) and
castration-recurrent tumors (Fig. 4 panel C, 3 and 6). In contrast, the 6-day castrate showed
substantial loss of 14-3-3η staining in nuclei while AR staining was detected but also weaker
than in the intact or castration-recurrent tumors. Earlier studies on AR expression in the CWR22
xenograft demonstrated a major loss of AR in nuclei 2 days post-castration with restoration to
about 60% of the intact by 6 days post-castration (5). Thus, during the first several days of
androgen deprivation, loss of AR activity with decreased nuclear localization of AR was
associated with decreased expression and nuclear localization of 14-3-3η. In striking contrast,
the castration-recurrent tumor exhibited increased expression of 14-3-3η and nuclear
localization with AR similar to that in androgen-stimulated tumors from intact mice.
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Immunostaining of a CWR22 xenograft tumor tissue microarray with the 14-3-3η specific
antibody indicated nuclear 14-3-3η levels were decreased by about 50% after 6 and 12 days
of androgen deprivation (P values < 0.001) and increased within 48 hours of testosterone
treatment, P values < 0.001 (Supplementary Table S1). In castration-recurrent tumors, nuclear
levels of 14-3-3η were similar to the levels in tumors from intact mice. 14-3-3η immunostaining
in cytoplasm was somewhat weaker and showed little change under the different conditions.
14-3-3 η is expressed in clinical specimens of BPH, androgen dependent and castration-
recurrent prostate cancer
14-3-3η protein was analyzed in clinical specimens of human prostate by immunostaining
using the 14-3-3η specific antibody (Santa Cruz, sc-17287, lot #K1803). In Fig. 5 are shown
representative sections of androgen-stimulated benign prostate (Fig. 5 A1), androgen-
stimulated prostate cancer (Fig. 5 A2) and castration-recurrent prostate cancer (Fig. 5 A3).
Immunostaining of tissue microarray sections included groups of 20 specimens each of benign
prostatic hyperplasia, androgen-stimulated prostate cancer and castration-recurrent prostate
cancer. Visual scoring of 14-3-3η staining showed no differences (P value > 0.05) among the
three groups and similar localization in nuclei and cytoplasm. Levels of AR were also similar
in the three groups, however AR was localized entirely in nuclei (Table 1).
Discussion
Our findings indicate that 14-3-3η promotes AR transcriptional activation in association with
its effects on mitogen signaling. 14-3-3 is known to have a critical role in the Ras-Raf signaling
pathway through which growth factors such as EGF activate ERK1/2 by a phosphorelay from
Ras-GTP and Raf1 (18). 14-3-3 maintains Raf-1 in an inactive state in the absence of activation
signals but promotes Raf-1 activation and stabilizes its active conformation when signals are
received, for example from EGF/heregulin receptors (18). Raf-1 may be activated directly by
a PKC-14-3-3η complex supporting another activation mechanism for the MAP system in
which 14-3-3 isoforms are also phosphorylated (32). Xing et al. (33) demonstrated that
dominant negative 14-3-3η inhibited serum stimulated ERK/MAPK activation.
The EGF/heregulin receptors HER1, 2, 3, and 4 are expressed in CWR-R1 cells and EGF and
heregulin activate signaling from these receptors through MAPK, phosphatidylinositol-3
kinase and AKT (17,34–36). In CWR-R1 cells EGF was shown to increase phosphorylation
of the p160 co-activator TIF2 as well as the interaction between phosphorylated forms of TIF2
and AR (27). Inhibition of HER-2/neu decreased AR recruitment to androgen response
elements (36). LNCaP cell growth is increased by the stable transfection of HER2/Neu and
HER2/Neu induces expression of prostate-specific antigen through the MAP kinase pathway
(17,34). 14-3-3η amplification of EGF/heregulin signaling may promote AR hypersensitivity
in prostate cancer (25,37) and our result showing 14-3-3η enhancement of AR transcriptional
activity at a low level of DHT is consistent with this concept. 14-3-3σ (sigma) increased the
transcriptional activity of AR in LNCaP cells in the absence of androgen and without a
detectable interaction with AR (38).
14-3-3 interactions with AR may provide a link with mitogen signaling not only through direct
effects on AR but also by modifying AR coregulators. Zilliacus et al. (31) reported that
14-3-3η binds AR, GR, ERα and ERβ in cell free pull-down assays. In addition, 14-3-3η bound
the nuclear receptor corepressor RIP140 and the coactivator ACTR, a member of the SRC3
family (31) that includes TRAM-1, AIB1 and RAC3 (39). A somewhat weaker interaction was
seen with SRC-1 and TIF2 (31). These p160 coregulators contain LXXLL motifs (40,41) that
mediate binding of the coregulators to activation function 2 (AF2) in the AR ligand binding
domain (42). 14-3-3η was shown to bind a GR fragment containing only the ligand binding
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domain (31). 14-3-3η contains the motif LXXFL with predicted α-helical secondary structure
in the center of its conserved amphipathic groove (18) suggesting it might bind AF2.
Coexpression of 14-3-3η with RIP140 in COS-7 cells promoted the cytoplasmic localization
of RIP140 and this effect of keeping RIP140 out of the nucleus was suggested as a mechanism
whereby 14-3-3η increased GR transcriptional activation (31). Since RIP140 interacts with AR
and can function as an AR corepressor (43), the action of 14-3-3η to sequester RIP140 in the
cytoplasm might also be a mechanism whereby 14-3-3η enhances the transcriptional activity
of AR. In contrast to its effect on RIP140, we observed under similar experimental conditions
in COS-7 cells that 14-3-3η promoted the nuclear localization of AR in the absence of androgen.
Furthermore, a major portion of 14-3-3η was in nuclei together with AR.
Phosphoserine motifs are established recognition sites for 14-3-3 binding. Numerous proteins
bind 14-3-3 through a phosphoserine recognition motif resembling the Raf-1 consensus motif
RSxpSxP (18–21,44,45). However, variations of the motif have been found where 14-3-3
binding partners have two imperfect sites or sometimes non-phosphorylated acidic motifs. AR
is a phosphoprotein with several known sites of serine phosphorylation in the NH2-terminal
domain and hinge regions (46–49). S650 is in the AR hinge region close to the nuclear transport
signal and phosphorylation of S650 promotes nuclear export of AR (47). Some phosphoserines
in AR might be sites for 14-3-3η binding and regulation of AR function even though they are
not in perfect consensus motifs. For example, 14-3-3η binding to pS650 might possibly
promote nuclear retention of AR by interfering with nuclear export.
In CWR-R1 cells, expression of 14-3-3η enhanced DHT and EGF induced AR transactivation
of both the PSA-luciferase and MMTV-luciferase reporter genes. The potentiating effect of
14-3-3η on AR transactivation of MMTV promoter was observed at a low concentration of
DHT and to a lesser extent with EGF alone in the absence of DHT suggesting that 14-3-3η
may be involved in mitogen activation of AR by a ligand independent mechanism. 14-3-3η
potentiation of AR transcriptional activity was additive when DHT was combined with EGF.
In addition to the 14-3-3η regulation of the MMTV and PSA reporter genes reported herein,
14-3-3η was reported to enhance androgen dependent AR transactivation of the CRISP-1
enhancer/promoter in transient transfection assays using the PC3 human prostate cancer cell
line (50).
Taken together with the androgen-induced increase in 14-3-3η gene expression, 14-3-3η
enhancement of AR transcriptional activity suggests there are mutual positive effects of
14-3-3η and AR in prostate cancer cells. Androgen dependence of 14-3-3η expression in the
CWR22 xenograft was demonstrated by a decline in both protein and mRNA within 6 days
following castration of tumor bearing mice and an increase in 14-3-3η expression in response
to testosterone treatment of 6 day castrate mice. 14-3-3η mRNA was also higher in castration-
recurrent CWR22 xenograft tumors than in tumors from the castrate mice. This increase in
expression of 14-3-3η in the castration-recurrent CWR22 tumor is characteristic of androgen
regulated genes in this model system (7) including the EGF receptor (51) and consistent with
the presence of a functionally active AR in the recurrent CWR22 xenograft despite the absence
of circulating testicular androgens. The relationship between 14-3-3η levels in androgen-
stimulated and castration-recurrent CWR22 xenografts is similar to that in clinical specimens
of androgen-stimulated and castration-recurrent cancers as noted by immunohistochemical
analysis of 14-3-3η in tissue microarray sections. Local tissue production of androgens that
activate AR may promote the expression of 14-3-3η in clinical castration-recurrent cancer
(12) and possibly in the CWR22 xenograft model as well. Androgen up-regulation of another
14-3-3 isoform, similar to 14-3-3ζ (zeta), was found in a proteomic analysis of LNCaP prostate
cancer cell protein lysates (52). Similarly, DHT stimulated an increase in 14-3-3σ (sigma)
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protein in M12 cells, an AR positive cell line derived from SV40 T-antigen immortalized non-
neoplastic human prostate epithelial cells (53).
14-3-3 ζ (zeta) is a heat shock protein regulated by heat stress in Drosophila S2 cells (54)
consistent with the heat shock protein-like functions of 14-3-3 in cell survival (55,56). The
stress induced heat shock factor (HSF1) a potent transcription factor for Hsp70 and Hsp90,
was shown to interact with its response element in the promoter region of the 14-3-3ζ gene
suggesting that HSF1 mediated the stress-induced transcription of 14-3-3ζ (54). HSF1 protein
was shown by western blot to be present in several prostate cancer cell lines. In addition,
immunostaining of HSF1 protein was higher in prostate carcinoma cells than in normal prostate
epithelial cells (57) suggesting that HSF1 is a positive selection factor in prostate cancer as a
consequence of its role in promoting cell survival. These findings, together with observations
that 14-3-3 levels are increased by androgen, raise the possibility that HSF1 expression or
activation might be increased by androgen and mediate the androgen induced increase in
14-3-3.
A potential link between androgen activation of AR and HSF1 was suggested with the
discovery that a highly conserved sequence in the AR NH2-terminal region is a binding site
for CHIP (C-terminus of Hsp70-interacting protein) (58,59). Hsp70 forms a stable complex
with the transactivation domain of HSF1 and thereby inhibits HSF1 transcriptional activity.
CHIP activates HSF1 by releasing it from Hsp70 inhibition. AR activation by androgen binding
drives AR into the nucleus and could dissociate CHIP from AR. CHIP would then be free to
activate HSF1 and increase activated HSF1 within the nucleus where it could stimulate 14-3-3
gene transcription.
The multifunctional nature of 14-3-3 suggests it may influence numerous signaling
mechanisms in prostate cancer cells. Our studies indicate that 14-3-3η has a role in promoting
the concerted actions of AR and EGF in castration-recurrent prostate cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Interaction between wildtype AR and 14-3-3η in vitro (A) Binding of [35S] AR to His-tagged
14-3-3η in the absence or presence of 1 μM DHT was assayed in three independent
experiments. AR bound 14-3-3η in the presence of DHT (mean & sd, NiSeph. control 9288 −/
+ 981, +DHT His-tagged 14-3-3η 15032 −/+ 2119, P value = 0.013) but not in the absence of
DHT. AR did not bind His-tagged 14-3-3ζ. (B) Left panel: AR co-immunoprecipitation with
14-3-3η from protein lysates of COS cells. Cells were co-transfected with AR and 14-3-3η
sense or antisense expression vector and incubated in the absence or presence of 1 nM DHT.
Immunoprecipitates from cell lysates with anti-14-3-3 antibody, Santa Cruz Biotechnology
sc-731 (lanes 1, 2, 5, 6) or anti-actin antibody (lanes 3, 4) were analysed by electrophoresis
and immunoblot as described in Methods using AR monoclonal antibody (Biogenex). The
positions of molecular weight markers (kDa) and migration of AR (Mr 112,000) are indicated.
Right panel: Cell extract controls showing immunoblots of AR and 14-3-3η in protein lysates
of cotransfected COS cells cultured with (lane 1) or without (lane 2) DHT. (C) Upper panel:
COS cells were transfected with either 14-3-3η, AR or the AR corepressor CRIF1 and cultured
in the presence or absence of 10 nM DHT. Lower panel: AR was co-transfected with
14-3-3η or CRIF1 into COS cells and cultured in the presence or absence of 10 nM DHT. AR
immunofluoresence is (red) and 14-3-3η or CRIF (green). AR co-localization with 14-3-3η or
CRIF is shown in merged images (yellow).
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(A) 14-3-3η stimulation of AR transcriptional activity. CV-1 cells in 6 cm culture dishes were
cotransfected with probasin-luciferase (0.25 μg) and wild-type AR (0.25 μg) together with
14-3-3η sense or antisense vectors (0.5 μg) and incubated in the absence or presence of 1 nM
DHT.
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14-3-3η stimulation of endogenous AR-H874Y transcriptional activity in CWR-R1 cells.
CWR-R1 cells in 6 cm culture dishes were cotransfected with (A) PSA-luciferase (0.5 μg) and
incubated with or without 0.1 nM DHT and 100 ng/ml EGF or (B) MMTV-luciferase (0.5 μg)
with or without 0.5 pM DHT and 10 ng/ml EGF. Both A and B cotransfections included
14-3-3η sense or antisense (0.25 μg). (C) Coimmunoprecipitation of endogenous AR and
14-3-3 in protein lysates of CWR-R1 cells cultured in the absence or presence of 0.1 nM DHT,
Upper panel: Cell protein lysates immunoblotted with AR antibody and 14-3-3η antibody
sc-731. Middle panel: Cell extract protein lysate immunoprecipitated with anti-14-3-3η
antibody sc-731 or control anti-actin antibody and immunoblotted with AR antibody. Lower
panel: Protein lysates from CWR-R1 cells cultured in the presence of 0.1 nM DHT with or
without 100ng/ml EGF were immunoprecipitated using anti-14-3-3 antibody sc-731 or control
anti-actin antibody and immunoblotted with AR antibody. (D) CWR-R1 cells cultured as above
in 6 cm dishes, were transfected with MMTV-luciferase (0.5 μg). Left panel: cells were
cotransfected with either pcDNA empty vector (0.25 μg) or pcDNA expressing the dominant
negative (DN)14-3-3η mutant (R 56,60 A) (0.25μg). Cells were incubated without or with DHT
or EGF, or with DHT+EGF. Right panel: cells were transfected with either pcDNA or DN
(0.125 μg) without or with pSG5-14-3-3η and incubated in the presence or absence of EGF
+DHT.
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Panel A: 14-3-3η mRNA assayed by quantitative RT-PCR in CWR22 xenograft tumors: intact
androgen-stimulated, 6 days post-castration (6 dcx), 6 days post-castration and 48 h after
injection of the host mouse with testosterone propionate 0.1 mg (6 dcx + T), 12 day post-
castration untreated (12 dcx) and castration-recurrent (CR). Panel B: (1–4) CWR22 tumors
immunostained with anti 14-3-3 antibody sc-731, Panel C: (1–3) CWR22 tumors stained with
14-3-3η antibody sc-17287 and (4-6) anti AR antibody. (B-1, C-1, C-4) CWR22 tumor from
intact mouse (B-2, C-2, C-5) CWR22 tumor from mouse 6 days post-castration (B-3) CWR22
tumor 6 days post-castration and 48 h after injection of mouse with testosterone propionate 0.1
mg, (B-4, C-3, C-6) castration-recurrent CWR22 tumor from mouse 150 days post-castration.
Images in panel B were reduced from X100 and images in panel C obtained with a X40 lens
using the SPOT-4 camera system were reduced from X400.
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14-3-3η immunostaining with sc-17287 in human prostate tissue microarray sections of clinical
specimens (27) (A) from: 1) benign prostate, untreated 2) prostate cancer, untreated 3)
castration-recurrent prostate cancer. All original images were reduced from X400. (B)
14-3-3η immunoblot using sc-17287 antibody and protein extracts prepared from random
samples of (1) benign prostate, untreated (2) prostate cancer, untreated (3) castration-recurrent
prostate cancer.
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Table 1
Nuclear and cytoplasmic visual scores of 14-3-3η and androgen receptor immunostaining in tissue microarrays
comprised of androgen-stimulated benign prostate, androgen-stimulated prostate cancer and castration-recurrent
prostate cancer (mean ± SEM).
Androgen-stimulated benign prostate Androgen-stimulated prostate cancer Castration-recurrent prostate cancer
14-3-3η Nuclear 255 ± 11 247 ± 19 256 ± 10
Cytoplasmic 246 ± 12 212 ± 25 255 ± 11
Androgen Receptor Nuclear 212 ± 5 225 ± 6 220 ± 6
Cytoplasmic 0 0 0
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